We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Depot Disulfiram for AIDS and ARC

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00002065
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
NIH AIDS Clinical Trials Information Service
  Purpose
To assess the safety and efficacy of depot disulfiram as a new treatment for AIDS and AIDS related complex.

Condition Intervention
HIV Infections Drug: Disulfiram

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Depot Disulfiram for AIDS and ARC

Resource links provided by NLM:


Further study details as provided by NIH AIDS Clinical Trials Information Service:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Patients must have a positive diagnosis of AIDS or AIDS related complex (ARC) according to the CDC criteria.

  • Also patient must be:
  • Able to understand the study.
  • Strongly motivated to participate in the study, and willing to comply with all the conditions specified in the informed consent forms.
  • Ambulatory and able to maintain an independent life outside the hospital.
  • Free of clinically significant organic disease affecting neurologic, hepatic, renal, and clinical status.

Patients must be free of clinically significant organic disease affecting neurologic, hepatic, renal, and clinical status.

Patients must be free of clinically significant organic disease affecting neurologic, hepatic, renal, and clinical status.

History of alcohol abuse.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002065


Locations
United States, New York
Saint Vincent's Med Ctr
Staten Island, New York, United States, 10310
Sponsors and Collaborators
St. Vincent's Medical Center
  More Information

ClinicalTrials.gov Identifier: NCT00002065     History of Changes
Other Study ID Numbers: 024A
First Submitted: November 2, 1999
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
Last Verified: November 1999

Keywords provided by NIH AIDS Clinical Trials Information Service:
Delayed-Action Preparations
Disulfiram
Acquired Immunodeficiency Syndrome
AIDS-Related Complex

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Disulfiram
Alcohol Deterrents
Acetaldehyde Dehydrogenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action